Aflibercept

Aflibercept

• CAS Number: 862111-32-8
• UNSPSC Description: Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease[1][2][3].
• Target Antigen: VEGFR
• Type: Inhibitory Antibodies
• Related Pathways: Protein Tyrosine Kinase/RTK
• Applications: Metabolism-protein/nucleotide metabolism
• Field of Research: Metabolic Disease; Cardiovascular Disease; Cancer
• Assay Protocol: https://www.medchemexpress.com/aflibercept.html
• Purity: 97.90
• Solubility: 10 mM in DMSO
• Smiles: [Aflibercept]
• References & Citations: [1]Klettner A, et al. Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis. Br J Ophthalmol. 2014 Oct;98(10):1448-52.|[2]Kim ID, et al. Aflibercept, a VEGF (Vascular Endothelial Growth Factor)-Trap, Reduces Vascular Permeability and Stroke-Induced Brain Swelling in Obese Mice. Stroke. 2021 Aug;52(8):2637-2648.|[3]Dong ZC, et al. The vascular endothelial growth factor trap aflibercept induces vascular dysfunction and hypertension via attenuation of eNOS/NO signaling in mice. Acta Pharmacol Sin. 2021 Sep;42(9):1437-1448.
• Shipping Conditions: Isolate blue ice and the product with bubble pack to avoid direct contact
• Storage Conditions: Store at 4°C for 2 years, do not freeze
• Clinical Information: Launched